SEC Form 4 · accession 0001209191-15-002628
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — EVP and COO
Period of report
Jan 4, 2015
Accepted (ET)
Jan 6, 2015 · 8:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2015 | A | 33,875 | $0.00 | A | 110,422 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $14.34 | Jan 4, 2015 | A | 67,750 | A | Jan 4, 2016 | Jan 4, 2025 | Common Stock | 67,750 | 67,750 | D |
Explanation of responses
- F1The 33,875 shares are restricted common stock, with one-third of the 33,875 shares vesting on January 4, 2016, and one-twelfth vesting on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.
- F2Includes 93,875 shares of restricted stock.
- F3The options vest according to the following schedule: one-third of the 67,750 options will vest on January 4, 2016, and one-twelfth will vest on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.